eLife · 2017 · 38 citations · 48 references
MedicineGeneticsOncologyGene ExpressionMolecular OncologyTranscriptional RegulationCancer Cell SignalingDna Damage SignalingOncogenic Signaling PathwaysSignal Transduction In CancerTumor Suppressor Gene InactivationTumor Suppressor GenesChromatin DomainsChromatin RemodelingHomozygous DeletionPromotersRna-protein BindingTumor Suppressor P53Tumor Suppressor Pathways
Tumor suppressor p53 prevents cell transformation by inducing apoptosis and other responses. Homozygous TP53 deletion occurs in various types of human cancers for which no therapeutic strategies have yet been reported. TCGA database analysis shows that the TP53 homozygous deletion locus mostly exhibits co-deletion of the neighboring gene FXR2, which belongs to the Fragile X gene family. Here, we demonstrate that inhibition of the remaining family member FXR1 selectively blocks cell proliferation in human cancer cells containing homozygous deletion of both TP53 and FXR2 in a collateral lethality manner. Mechanistically, in addition to its RNA-binding function, FXR1 recruits transcription factor STAT1 or STAT3 to gene promoters at the chromatin interface and regulates transcription thus, at least partially, mediating cell proliferation. Our study anticipates that inhibition of FXR1 is a potential therapeutic approach to targeting human cancers harboring TP53 homozygous deletion.
48
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz et al. · Science Signaling · 2013 · 15.9K citations · Full text
Medicine, Bioinformatics, Oncology +17
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong, F. Ann Ran, David Cox et al. · Science · 2013 · 15.7K citations